Who is building them · What platform · Who is paying

Overview

Twenty-one named plague-vaccine programmes. Six are already in people. One new-generation shot has a marketing authorisation, in Russia. None is approved in the United States or the European Union.

Candidates

In humans

Licensed, Russia 2024

RNA platforms

Approved in US or EU

Each programme

One bar per vaccine, coloured by platform. Drag the year to dim programmes that were not yet on the record.

Year2026

01 EV76-NIIEG 02 PMMM — microencapsulated rF1 + rV 03 rF1V + CpG 1018 04 Native F1 + rV in alum 05 ChAdOx1 Plague (F1 + V)06 rF1V + flagellin adjuvant 07 F1 mRNA-LNP — single dose 08 Bivalent F1 + LcrV mRNA-LNP 09 Self-amplifying RNA-LNP, F1 + V 10 Ad5-YFV — YscF / F1 / LcrV 11 CO92 ΔlppΔmsbBΔail / Δpla (LMA, LMP)12 CO92 Δpgm / ΔpPst · ΔyscN 13 EV76-B-SHUΔpla 14 VTnF1 — oral, single dose 15 Outer-membrane vesicles + modified LPS 16 Salmonella Typhimurium — F1 / Psn / V 17 F. tularensis LVS — F1 / LcrV + anthrax PA 18 Bacteriophage T4 nanoparticle — F1-V + PA 19 Polyanhydride nanovaccine — rF1V 20 DNA fusion vaccine — anthrax / plague 21 Peptidoglycan-free bacterial ghosts

Listed company

One of the twenty-one programmes has a public owner. The rest are state institutes, universities, or defense laboratories.

03 rF1V + CpG 1018

Sanofi Nasdaq:SNY

$40.20+0.64 (+1.62%)

Last close on file · 7 Oct 2026, 16:00 EDT

Sanofi bought Dynavax in February 2026. Dynavax supplied CpG 1018 and this rF1V candidate, then left the Nasdaq. Its last print was $15.50 on 9 February 2026. The US Department of Defense still funds the trial.

Where the work sits

Amber is already in humans. Stone is still in animals. Click a bar to open that country.

Platform mix

Click a bar to filter the pipeline.

Already in humans

Open in pipeline

Stages, dates, and funders follow one briefing — not a live regulator feed. EV76 is counted in both Russia and China on the country chart. This is not medical advice.